BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

662 related articles for article (PubMed ID: 17363536)

  • 1. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
    Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
    J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
    Niwakawa M; Hashine K; Yamaguchi R; Fujii H; Hamamoto Y; Fukino K; Tanigawa T; Sumiyoshi Y
    Invest New Drugs; 2012 Jun; 30(3):1046-54. PubMed ID: 21246251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
    Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
    Jonasch E; Corn P; Pagliaro LC; Warneke CL; Johnson MM; Tamboli P; Ng C; Aparicio A; Ashe RG; Wright JJ; Tannir NM
    Cancer; 2010 Jan; 116(1):57-65. PubMed ID: 19862815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
    Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
    Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
    Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
    Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
    Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
    Procopio G; Verzoni E; Bracarda S; Ricci S; Sacco C; Ridolfi L; Porta C; Miceli R; Zilembo N; Bajetta E
    Br J Cancer; 2011 Apr; 104(8):1256-61. PubMed ID: 21448165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
    Bracarda S; Porta C; Boni C; Santoro A; Mucciarini C; Pazzola A; Cortesi E; Gasparro D; Labianca R; Di Costanzo F; Falcone A; Cinquini M; Caserta C; Paglino C; De Angelis V
    Eur Urol; 2013 Feb; 63(2):254-61. PubMed ID: 22964169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
    Amato RJ; Flaherty AL; Stepankiw M
    Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
    Davies MA; Fox PS; Papadopoulos NE; Bedikian AY; Hwu WJ; Lazar AJ; Prieto VG; Culotta KS; Madden TL; Xu Q; Huang S; Deng W; Ng CS; Gupta S; Liu W; Dancey JE; Wright JJ; Bassett RL; Hwu P; Kim KB
    Clin Cancer Res; 2012 Feb; 18(4):1120-8. PubMed ID: 22223528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.